

# HOT TOPICS IN CARDIOLOGIA 2024

27 e 28 Novembre 2024

Villa Doria D'Angri - Via F. Petrarca 80,  
Napoli

Cuore e Diabete  
Press Review



**LIVE**  
**BREAKING**  
**NEWS**

Dott. Gerardo Carpinella  
UOC Cardiologia UTIC ed  
Emodinamica  
AORN A. Cardarelli



# Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Milton Packer, M.D., Michael R. Zile, M.D., Christopher M. Kramer, M.D., Seth J. Baum, M.D., Sheldon E. Litwin, M.D., Venu Menon, M.D., Junbo Ge, M.D., Govinda J. Weerakkody, Ph.D., Yang Ou, Ph.D., Mathijs C. Bunck, M.D., Karla C. Hurt, B.S.N., Masahiro Murakami, M.D., and Barry A. Borlaug, M.D., for the SUMMIT Trial Study Group\*

This article was published on November 16, 2024, at NEJM.org.


- Double blind 1:1 RCT
- 731 pazienti (gruppo tirzepatide e gruppo placebo)
- Periodo medio follow up 104 settimane
- Endpoint primari: mortalità cardiovascolare e peggioramento HF
- 48% pazienti diabetici
- 45% donne
- Hazard ratio a favore del trattamento con tirzepatide per i pazienti diabetici sia per quanto riguarda end point primario sia per qualità di vita (valutata con Kansas City Score)



# Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Milton Packer, M.D., Michael R. Zile, M.D., Christopher M. Kramer, M.D., Seth J. Baum, M.D., Sheldon E. Litwin, M.D., Venu Menon, M.D., Junbo Ge, M.D., Govinda J. Weerakkody, Ph.D., Yang Ou, Ph.D., Mathijs C. Bunck, M.D., Karla C. Hurt, B.S.N., Masahiro Murakami, M.D., and Barry A. Borlaug, M.D., for the SUMMIT Trial Study Group\*

This article was published on November 16, 2024, at NEJM.org.



History of type 2 diabetes

Yes	16/174	28/178		0.58 (0.31 to 1.07)		6.23 (1.77 to 10.70)
No	20/190	28/189		0.66 (0.37 to 1.18)		7.47 (2.67 to 12.26)



# Tirzepatide for Obesity Treatment and Diabetes Prevention

Ania M. Jastreboff, M.D., Ph.D., Carel W. le Roux, F.R.C.P., Ph.D., Adam Stefanski, M.D., Ph.D., Louis J. Aronne, M.D., Bruno Halpern, M.D., Ph.D., Sean Wharton, M.D., Pharm.D., John P.H. Wilding, D.M., Leigh Perreault, M.D., Shuyu Zhang, M.S., Ramakrishna Battula, M.S., Mathijs C. Bunck, M.D., Ph.D., Nadia N. Ahmad, M.D., M.P.H., and Irina Jouravskaya, M.D., Ph.D., for the SURMOUNT-1 Investigators\*

This article was published on November 13, 2024, at NEJM.org.

- Phase 3 1:1:1:1 RCT (placebo vs tirzepatide a diverso dosaggio)
- > 3000 pz di cui 1000 con prediabete
- 63% donne
- Lungo follow-up (fino a 194 settimane)
- Primary end point su riduzione peso e secondary end point su insorgenza di diabete




# Tirzepatide for Obesity Treatment and Diabetes Prevention

Ania M. Jastreboff, M.D., Ph.D., Carel W. le Roux, F.R.C.P., Ph.D., Adam Stefanski, M.D., Ph.D., Louis J. Aronne, M.D., Bruno Halpern, M.D., Ph.D., Sean Wharton, M.D., Pharm.D., John P.H. Wilding, D.M., Leigh Perreault, M.D., Shuyu Zhang, M.S., Ramakrishna Battula, M.S., Mathijs C. Bunck, M.D., Ph.D., Nadia N. Ahmad, M.D., M.P.H., and Irina Jouravskaya, M.D., Ph.D., for the SURMOUNT-1 Investigators\*

This article was published on November 13, 2024, at NEJM.org.

## C Incidence of Type 2 Diabetes

### C Changes in Glycemic Status from Baseline to Week 176 and Week 193





# Intensive Blood-Pressure Control in Patients with Type 2 Diabetes

Y. Bi, M. Li, Y. Liu, T. Li, J. Lu, P. Duan, F. Xu, Q. Dong, Ailiang Wang, T. Wang, R. Zheng, Y. Chen, M. Xu, X. Wang, Xinhuan Zhang, Y. Niu, Z. Kang, C. Lu, Jing Wang, X. Qiu, An Wang, S. Wu, J. Niu, Jingya Wang, Z. Zhao, H. Pan, X. Yang, X. Niu, S. Pang, Xiaoliang Zhang, Y. Dai, Q. Wan, S. Chen, Q. Zheng, S. Dai, J. Deng, L. Liu, G. Wang, H. Zhu, W. Tang, H. Liu, Z. Guo, G. Ning, J. He, Y. Xu, and W. Wang, for the BPROAD Research Group\*

This article was published on November 16, 2024, at NEJM.org.

- RCT multicentrico cinese
- 12000 pazienti
- 45% donne
- Lungo follow-up (circa 6 anni)
- Primary end point: composito infarto e stroke non fatali, ospedalizzazione per HF e mortalità cardiovascolare





# Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial



**FIGURE 1** Cumulative Incidence Plots Showing the Time From Randomization to the First HF Event


Ric  
Vla  
Ric  
Th  
Flo







## Different associations of atherogenic index of plasma, triglyceride glucose index, and hemoglobin A1C levels with the risk of coronary artery calcification progression according to established diabetes



**Fig. 1** Comparison of baseline CACS according to diabetic status. CACS coronary artery calcium score

**Fig. 2** Incidence of CAC progression according to diabetic status. CAC coronary artery calcification



Thank You for  
your attention